Literatür Detay Bilgisi
Phase II study of Melphalan, Thalidomide and Prednisone (MPT) combined with oral Panobinostat in patients with relapsed/refractory MM.
Yazarlar : Offidani M, Polloni C, Cavallo F, et al
Yayın : Leuk Lymphoma.
Yayın Yılı : 2012
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22335534
Konu : Myelom
Literatür İçeriği :
Abstract
Abstract The combination of melphalan, prednisone, and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM). Panobinostat is a potent oral pan-deacetylase (pan-DACi) inhibitor. In preclinical and clinical studies, panobinostat showed good anti-myeloma activity in combination with several agents. This phase II study evaluated the combination of a fixed dose of MPT with escalating doses of panobinostat (three times weekly for 3 weeks, followed by a 9-day rest period) in relapsed/refractory MM. We used a two stage design to determine whether the combination was safe and effective. At least partial response was observed in 38.5% of patients. The maximum tolerated dose of panobinostat in combination with MPT could not be determined due to the high rate of dose-limiting toxicities experienced with panobinostat at a doses of 10 and 15 mg. The most common grade 3/4 adverse events were neutropenia (71%) and thrombocytopenia (35.5%). In conclusion, MPT in combination with panobinostat three times weekly for three weeks followed by a 9-day rest period is not well tolerated in patients with relapsed/refractory MM. Future studies should evaluate alternative dose schedules of panobinostatKonusu Aynı Olan Diğer Materyaller
| Sunumlar | Videolar | Olgu Tartışması |
